Olema insiders sell millions amid analyst upgrades now
Read, Watch or Listen
United States — Olema Pharmaceuticals executives sold shares between December 19 and December 23, 2025, according to Securities and Exchange Commission filings. Chief Medical Officer Naseem Zojwalla sold $7.5 million of common stock and exercised options; Director Ian T. Clark sold $7.87 million and exercised options; David Myles sold about $1.55 million and reported ownership changes. The moves coincided with analyst price‑target increases following interim results from Roche’s Phase 3 lidERA trial and with market volatility in OLMA shares. All transactions were disclosed via SEC filings and reported by financial news services. Based on 6 articles reviewed and supporting research.
About this summary
Prepared by Christopher Adams and reviewed by editorial team.
Timeline of Events
- Prior to December 2025: Olema develops OP-1250 (SERD/CERAN) as lead candidate in women's cancers.
- Mid-December 2025: Roche presents interim data from its Phase 3 lidERA trial, increasing industry focus on SERD class.
- Following the presentation: Analysts (H.C. Wainwright, Goldman Sachs, Jefferies) raise price targets for Olema and peers.
- December 19, 2025: SEC filings show David Myles and Ian T. Clark sold shares and exercised options.
- December 19–23, 2025: CMO Naseem Zojwalla sold shares and exercised options; financial outlets report market reactions.
- Articles Published:
- 4
- Right Leaning:
- 0
- Left Leaning:
- 0
- Neutral:
- 4
- Distribution:
- Left 0%, Center 100%, Right 0%
Company insiders realized personal liquidity through disclosed sales while analysts and some investors benefited from clearer price targets and updated valuations following Roche lidERA interim data.
Short-term shareholders and traders exposed to OLMA volatility experienced increased uncertainty and potential unrealized losses amid price swings after the disclosures.
Coverage of Story:
From Left
No left-leaning sources found for this story.
From Center
Olema insiders sell millions amid analyst upgrades now
Investing.com Investing.com South Africa Market Screener InsiderTrades.comFrom Right
No right-leaning sources found for this story.
Comments